Aethlon Medical, Inc. (AEMD)
NASDAQ: AEMD · Real-Time Price · USD
2.850
-0.090 (-3.06%)
Dec 17, 2025, 4:00 PM EST - Market closed
Aethlon Medical Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
9
Market Cap
2.17M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | 574.25K | 280.08K | 95.21% |
| Mar 31, 2022 | 294.17K | -364.94K | -55.37% |
| Mar 31, 2021 | 659.10K | 8.92K | 1.37% |
| Mar 31, 2020 | 650.19K | 420.56K | 183.15% |
| Mar 31, 2019 | 229.63K | 80.00K | 53.47% |
| Mar 31, 2018 | 149.63K | -242.45K | -61.84% |
| Mar 31, 2017 | 392.07K | -494.50K | -55.78% |
| Mar 31, 2016 | 886.57K | 124.16K | 16.28% |
| Mar 31, 2015 | 762.42K | -861.35K | -53.05% |
| Mar 31, 2014 | 1.62M | 393.77K | 32.01% |
| Mar 31, 2013 | 1.23M | -129.62K | -9.53% |
| Mar 31, 2012 | 1.36M | - | - |
| Mar 31, 2011 | - | - | - |
| Mar 31, 2010 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AEMD News
- 13 days ago - Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million - PRNewsWire
- 16 days ago - Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs - PRNewsWire
- 5 weeks ago - Aethlon Medical, Inc. (AEMD) Q2 2026 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update - PRNewsWire
- 5 weeks ago - Aethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025 - PRNewsWire
- 2 months ago - Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial - PRNewsWire
- 3 months ago - Aethlon Medical Announces Pricing of $4.5 Million Public Offering - PRNewsWire
- 3 months ago - Aethlon Medical Announces Issuance of Hemopurifier® Patents for the Treatment of Long COVID and COVID-19-associated Coagulopathy (CAC) - PRNewsWire